Osteopenia 发表于 2025-3-21 18:36:19
书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0668405<br><br> <br><br>书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0668405<br><br> <br><br>书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0668405<br><br> <br><br>书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0668405<br><br> <br><br>书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0668405<br><br> <br><br>书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0668405<br><br> <br><br>书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0668405<br><br> <br><br>书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0668405<br><br> <br><br>书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0668405<br><br> <br><br>书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0668405<br><br> <br><br>Pandemic 发表于 2025-3-21 20:37:58
Novel Immunomodulatory Pathways in the Immunoglobulin Superfamily,l domains consist of two “sheets” that consist of beta-strands, as illustrated for a generic Ig-domain (Fig. .). Many IgSF proteins consist of single chains that string together one or more Ig-domains, each with its own intrinsic features. IgSF proteins can have from one to many such domains, and thFICE 发表于 2025-3-22 02:00:39
http://reply.papertrans.cn/67/6685/668405/668405_3.png有恶臭 发表于 2025-3-22 04:45:21
NK Cell Responses in Immunotherapy: Novel Targets and Applications,reviously thought (O’Leary et al. (Nat. Immunol. .507–16, 2006); Nabekura and Lanier (J. Exp. Med. .2455–65, 2014), Sun et al. (Eur. J. Immunol. .2059–64., 2009)), perhaps making them even more attractive as tools to optimize the antitumor immune response. Herein, we review some of the basic biologyexorbitant 发表于 2025-3-22 10:36:50
Reversing T Cell Dysfunction for Tumor Immunotherapy,ICR “blockade” is the result of interfering with ICR:ligand interactions on exhausted T cells that preferentially express these markers. However, in some cases, ICR antibodies may actually enhance residual T cell function more directly. In addition, it will be important to consider the contributionDRAFT 发表于 2025-3-22 14:19:42
Immunomodulation Within a Single Tumor Site to Induce Systemic Antitumor Immunity: In Situ Vaccinatnse against tumor-associated antigens (TAAs) while avoiding normal host cells. This strategy has proven difficult because TAAs are highly variable in their immunogenicity and undergo immune editing to escape recognition. In addition, they can differ between tumor types and more importantly between i边缘 发表于 2025-3-22 20:56:17
http://reply.papertrans.cn/67/6685/668405/668405_7.pngMhc-Molecule 发表于 2025-3-22 21:21:00
http://reply.papertrans.cn/67/6685/668405/668405_8.png重画只能放弃 发表于 2025-3-23 01:43:04
Targeting the Physicochemical, Cellular, and Immunosuppressive Properties of the Tumor Microenvironstitial fluid interstitial fluid pressure (IFP), reduced perfusion, increased hypoxia), enhanced metastasis, tumor cell cloaking from immune cells, and immune system dysregulation. Experimental studies with PEGPH20, an investigational drug candidate currently in clinical development, have demonstrat陈旧 发表于 2025-3-23 07:16:52
Book 2016ins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating r